GlassScriptPhysician profile
Fern Daum Kumar
NPI 1992729396
$2,058.24
in general payments reported to CMS, 2019-2025
19 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.53 · 2022: $127 · 2023: $19.62 · 2024: $637 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $698.68 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $294.36 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $220.50 | 2022-2025 | |
| Pfizer INC. | $145.66 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.18 | 2025 | |
| Merck Sharp & Dohme LLC | $82.82 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Boston Scientific Corporation | $77.33 | 2025 | Enroute Transcarotid Neuroprotection System |
| Lilly USA, LLC | $68.05 | 2021-2025 | Zepbound, Mounjaro |
| Amgen INC. | $67.36 | 2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $55.14 | 2021-2024 | Shingrix, Arexvy |
| Medtronic, INC. | $54.84 | 2024-2025 | Minimed 780g |
| Kowa Pharmaceuticals America, INC. | $30.55 | 2025 | Zoryve |
| Exact Sciences Corporation | $25.64 | 2025 | The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $23.15 | 2025 | Trintellix |
| Abbott Laboratories | $18.66 | 2024 | Freestyle Libre 3 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $17.49 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.47 | 2024 | Xifaxan, Trulance |
| Currax Pharmaceuticals LLC | $14.37 | 2024 | Contrave |
| Amarin Pharma, INC. | $13.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fern Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.